keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C genotype 3

keyword
https://www.readbyqxmd.com/read/28809742/treatment-of-chronic-hcv-infection-with-the-new-direct-acting-antivirals-daa-first-report-of-a-real-world-experience-in-southern-brazil
#1
Hugo Cheinquer, Hoel Sette-Jr, Fernando H Wolff, Alexandre de Araujo, Silvia Coelho-Borges, Silvia R P Soares, Mauricio F A Barros
INTRODUCTION AND AIM: There is almost no data regarding the efficacy of direct acting antivirals (DAAs) therapy in Brazil. The aim of this historical cohort study is to describe the sustained virologic response (SVR) rate among real-world compensated chronic hepatitis C patients in three hepatology centers from Southern Brazil. MATERIALS AND METHODS: Patients were included if they had at least 12 weeks follow-up after the end of therapy. Patients that were lost to follow-up or had treatment prematurely interrupted for any reason were considered treatment failure in this intention to treat analysis...
August 8, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28809740/early-successes-in-an-open-access-provincially-funded-hepatitis-c-treatment-program-in-prince-edward-island
#2
Daniel Smyth, Jordan W Francheville, Robin Rankin, Jeremy Beck, Connie Hoare, Stefanie Materniak, Greg German, Lisa Barrett, Natalie Bunimov-Wall
INTRODUCTION: The availability of curative hepatitis C therapies has created an opportunity to improve delivery and access. Local providers, government, industry, and community groups in Prince Edward Island developed an innovative province-wide care model. Our goal was to describe the first year of program implementation. MATERIAL AND METHODS: Using a community based prospective observational study design, all chronic hepatitis C referrals received from April 2015 to April 2016 were recorded in a database...
August 8, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28807261/association-between-hepatitis-c-virus-and-chronic-kidney-disease-heterogeneity-begets-heterogeneity
#3
Gregory M Lucas
Epidemiologic studies examining the association between hepatitis C virus and chronic kidney disease have yielded conflicting findings. Analyzing data from a Taiwanese cohort, Lai and colleagues report a novel finding that the odds of chronic kidney disease were nearly 3-fold higher in hepatitis C virus-infected persons with genotype 2 compared with genotype 1. Hepatitis C virus genotype distributions differ in regions around the world. Can genotypic differences in chronic kidney disease risk explain some of the heterogeneity in prior studies?...
September 2017: Kidney International
https://www.readbyqxmd.com/read/28806922/hepatitis-b-reactivation-characterized-by-hbsag-negativity-and-anti-hbsag-antibodies-persistence-in-haematopoietic-stem-cell-transplanted-patient-after-lamivudine-withdrawal
#4
C Cerva, G Maffongelli, V Svicher, R Salpini, L Colagrossi, A Battisti, B Mariotti, R Cerretti, L Cudillo, L Sarmati
BACKGROUND: HBV reactivation is associated with high mortality rates in hematopoietic stem cell transplantation (HSCT) and prophylactic lamivudine (LMV) treatment is suggested to prevent this phenomenon. However, the duration of LMV treatment in HSCT patients is not fully defined and the time of immune recovery is considered the best parameter for a drug to be safely interrupted. In patients undergoing allogeneic HSCT, the time of immune recovery is not easy to define and may take years after transplantation and prolonged LMV treatments, which can lead to drug-resistant viral strains...
August 15, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28802816/safety-and-efficacy-of-an-8-week-regimen-of-grazoprevir-plus-ruzasvir-plus-uprifosbuvir-compared-with-grazoprevir-plus-elbasvir-plus-uprifosbuvir-in-participants-without-cirrhosis-infected-with-hepatitis-c-virus-genotypes-1-2-or-3-c-crest-1-and-c-crest-2-part
#5
Edward J Gane, Stephen Pianko, Stuart K Roberts, Alexander J Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben-Ari, Graham R Foster, Kosh Agarwal, Alex L Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Doreen Fernsler, Jerry J Li, Anjana Grandhi, Hong Liu, Feng-Hsiu Su, Shuyan Wan, Zhen Zeng, Huei-Ling Chen, Frank J Dutko, Bach-Yen T Nguyen, Janice Wahl, Michael N Robertson, Eliav Barr, Wendy W Yeh, Rebeca M Plank, Joan R Butterton, Rafael Esteban
BACKGROUND: New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability of these combination regimens in individuals infected with genotypes 1, 2, or 3...
August 9, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28802814/safety-and-efficacy-of-a-fixed-dose-combination-regimen-of-grazoprevir-ruzasvir-and-uprifosbuvir-with-or-without-ribavirin-in-participants-with-and-without-cirrhosis-with-chronic-hepatitis-c-virus-genotype-1-2-or-3-infection-c-crest-1-and-c-crest-2-part-b-two
#6
Eric Lawitz, Maria Buti, John M Vierling, Piero L Almasio, Savino Bruno, Peter J Ruane, Tarek I Hassanein, Beat Muellhaupt, Brian Pearlman, Ligita Jancoriene, Wei Gao, Hsueh-Cheng Huang, Aimee Shepherd, Brynne Tannenbaum, Doreen Fernsler, Jerry J Li, Anjana Grandhi, Hong Liu, Feng-Hsiu Su, Shuyan Wan, Frank J Dutko, Bach-Yen T Nguyen, Janice Wahl, Michael N Robertson, Eliav Barr, Wendy W Yeh, Rebeca M Plank, Joan R Butterton, Eric M Yoshida
BACKGROUND: There is a need for hepatitis C virus (HCV) therapies with excellent efficacy across genotypes and in diverse populations. Part A of the C-CREST-1 and C-CREST-2 trials led to the selection of a three-drug regimen of grazoprevir (MK-5172; an HCV NS3/4A protease inhibitor; 100 mg/day) plus ruzasvir (MK-8408; an NS5A inhibitor; 60 mg/day) plus uprifosbuvir (MK-3682; an HCV NS5B polymerase inhibitor; 450 mg/day). Part B of the studies tested this combination as a single formulation in different treatment durations in a broader population...
August 9, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28800730/genotypes-of-hepatitis-a-virus-in-turkey-first-report-and-clinical-profile-of-children-infected-with-sub-genotypes-ia-and-iiia
#7
Huseyin Yilmaz, Asiye Karakullukcu, Nuri Turan, Utku Y Cizmecigil, Aysun Yilmaz, Ayse A Ozkul, Ozge Aydin, Alper Gunduz, Mahmut Mete, Fadile Y Zeyrek, Taner T Kirazoglu, Juergen A Richt, Bekir Kocazeybek
BACKGROUND: Hepatitis A virus (HAV) is a food and water-borne virus causing clinical (mainly hepatitis) and subclinical disease in humans. It is important to characterize circulating strains of HAV in order to prevent HAV infections using efficacious vaccines. The aim of this study was the detection and characterization of the circulating strains of HAV in Turkey by performing serology, RT-PCR, sequencing and phylogenetic analysis. METHODS: In this study, 355 HAV suspected cases were analysed by ELISA for the presence of antibodies to HAV...
August 11, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28797326/severe-liver-disease-related-to-chronic-hepatitis-c-virus-infection-in-treatment-naive-patients-epidemiological-characteristics-and-associated-factors-at-first-expert-centre-visit-france-2000-to-2007-and-2010-to-2014
#8
Alice Sanna, Yann Le Strat, Françoise Roudot-Thoraval, Sylvie Deuffic Burban, Patrizia Carrieri, Elisabeth Delarocque-Astagneau, Christine Larsen
Given recent profound improvements in the effectiveness of antiviral treatment for chronic Hepatitis C virus (HCV) infection, we aimed to describe the characteristics of patients referred to hepatology expert centres in France from 2000 to 2007 and from 2010 to 2014, and to identify factors associated with severe liver disease at their first visit for evaluation. We analysed data from two sources covering all of France: the former hepatitis C surveillance network, which included patients between 2000 and 2007, and the ANRS CO22 HEPATHER multi-centre cohort, which included patients between 2012 and 2014...
July 27, 2017: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
https://www.readbyqxmd.com/read/28797159/clinical-implication-of-serum-uric-acid-level-in-pegylated-interferon-and-ribavirin-combination-therapy-for-chronic-hepatitis-c-infection
#9
In Soo Oh, Joung Won Won, Hyung Joon Kim, Hyun Woong Lee
Background/Aims: Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment response have been identified. The aim of this study was to evaluate the efficacy and safety of combined PEG-IFN plus RBV and to examine the value of serum uric acid as a predictive factor in the treatment of chronic hepatitis C. Methods: A total of 74 patients chronically infected with HCV were enrolled between December 2004 and June 2009...
August 11, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28797039/impact-of-pnpla3-and-ifnl3-polymorphisms-on-hepatic-steatosis-in-asian-patients-with-chronic-hepatitis-c
#10
Chao-Min Huang, Kuo-Chin Chang, Chao-Hung Hung, King-Wah Chiu, Sheng-Nan Lu, Jing-Houng Wang, Chien-Hung Chen, Kwong-Ming Kee, Yuan-Hung Kuo, Ming-Chao Tsai, Po-Lin Tseng, Ming-Tsung Lin, Cheng-Kun Wu, Tsung-Hui Hu, Chung-Lung Cho, Yi-Hao Yen
BACKGROUND AND AIMS: A recent meta-analysis revealed that the genotype PNPLA3 rs738409 GG is associated with a higher risk of hepatic steatosis (HS) in Caucasian patients with chronic hepatitis C (CHC). However, controversial results were found regarding Asian populations. Furthermore, previous studies have shown a negative association between interferon lambda 3 (IFNL3) rs12979860 CC and HS in Caucasian CHC patients, but there have been no reports indicating any such association in Asian populations...
2017: PloS One
https://www.readbyqxmd.com/read/28790832/combination-of-sofosbuvir-and-daclatasvir-in-the-treatment-of-genotype-3-chronic-hepatitis-c-virus-infection-in-patients-on-maintenance-hemodialysis
#11
Jan Sperl, Sona Frankova, Miluse Kreidlova, Dusan Merta, Monika Tothova, Julius Spicak
Chronic hepatitis C virus infection (HCV) has a negative impact on the long-term survival of recipients of kidney transplants. HCV should be treated in hemodialyzed patients before their enlistment for kidney transplantation in order to avoid the reactivation of virus after transplantation. Direct-acting antivirals represent the current standard of care in hemodialyzed patients with HCV genotypes 1 and 4; in patients with genotypes 2 or 3, the optimal regimen is yet to be established. Sofosbuvir (SOF) and daclatasvir (DCV) represent an antiviral pangenotypic regimen with favorable pharmacokinetics in hemodialyzed patients...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28783179/reciprocal-antagonism-between-the-netrin-1-receptor-uncoordinated-phenotype-5a-unc5a-and-the-hepatitis-c-virus
#12
M-L Plissonnier, T Lahlali, M Raab, M Michelet, C Romero-López, M Rivoire, K Strebhardt, D Durantel, M Levrero, P Mehlen, F Zoulim, R Parent
Hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC), mainly through cirrhosis induction, spurring research for a deeper understanding of HCV versus host interactions in cirrhosis. The present study investigated crosstalks between HCV infection and UNC5A, a netrin-1 dependence receptor that is inactivated in cancer. UNC5A and HCV parameters were monitored in patients samples (n=550) as well as in in vitro. In patients, UNC5A mRNA expression is significantly decreased in clinical HCV(+) specimens irrespective of the viral genotype, but not in (HBV)(+) liver biopsies, as compared to uninfected samples...
August 7, 2017: Oncogene
https://www.readbyqxmd.com/read/28783119/characterization-of-naturally-occurring-ns5a-and-ns5b-polymorphisms-in-patients-infected-with-hcv-genotype-3a-treated-with-direct-acting-antiviral-agents
#13
Barbara Bartolini, Emanuela Giombini, Chiara Taibi, Raffaella Lionetti, Marzia Montalbano, Ubaldo Visco-Comandini, Gianpiero D'Offizi, Maria Rosaria Capobianchi, Fiona McPhee, Anna Rosa Garbuglia
Hepatitis C virus (HCV) genotype (GT)3 is associated with increased risk of steatosis, development of cirrhosis and hepatocellular carcinoma. Limited data are available regarding genetic variability and use of direct-acting antiviral agents in these patients. non-structural protein 5A (NS5A) and non-structural protein 5B (NS5B) sequencing was performed on 45 HCV GT3-infected Italian patients subsequently treated with sofosbuvir ± daclatasvir (SOF ± DCV). Novel GT3a polymorphisms were observed by Sanger sequencing in three NS5A (T79S, T107K, and T107S) and three NS5B (G166R, Q180K, and C274W) baseline sequences in patients who achieved sustained virological response (SVR)...
August 7, 2017: Viruses
https://www.readbyqxmd.com/read/28782338/sofosbuvir-for-the-treatment-of-hepatitis-c-genotype-3-infected-patients-in-pakistan
#14
Tayyab Saeed Akhter, Muhammad Umar, Hammama-Tul-Bushra Khaar, Faiza Aslam, Gul Nisar, Aqsa Naseer, Sadia Ahmad, Muhammad Osama
Background: This study was conducted to determine the viral responses of patients with chronic infection of Hepatitis C virus treated with sofubuvir. Methods: This Quasi experimental study was conducted at Centre for Liver and Digestive Diseases, Holy Family Hospital, Rawalpindi from September 2014 to September 2016. 502 patients with HCV genotype 3 including treatment naive, non-responders or relapsers to previous interferon based therapy along with patients having decompensated cirrhosis (child class B or C) were included in the study...
October 2016: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28780423/cinnamic-acid-derivatives-inhibit-hepatitis-c-virus-replication-via-the-induction-of-oxidative-stress
#15
Ryota Amano, Atsuya Yamashita, Hirotake Kasai, Tomoka Hori, Sayoko Miyasato, Setsu Saito, Hiromasa Yokoe, Kazunori Takahashi, Tomohisa Tanaka, Teruhime Otoguro, Shinya Maekawa, Nobuyuki Enomoto, Masayoshi Tsubuki, Kohji Moriishi
Several cinnamic acid derivatives have been reported to exhibit antiviral activity. In this study, we prepared 17 synthetic cinnamic acid derivatives and screened them to identify an effective antiviral compound against hepatitis C virus (HCV). Compound 6, one of two hit compounds, suppressed the viral replications of genotypes 1b, 2a, 3a, and 4a with EC50 values of 1.5-8.1 μM and SI values of 16.2-94.2. The effect of compound 6 on the phosphorylation of Tyr(705) in signal transducer and activator of transcription 3 (STAT3) was investigated because a cinnamic acid derivative AG490 was reported to suppress HCV replication and the activity of Janus kinase (JAK) 2...
August 2, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28768846/clinical-phenotype-and-outcome-of-hepatitis-e-virus-associated-neuralgic-amyotrophy
#16
Jeroen J J van Eijk, Harry R Dalton, Paolo Ripellino, Richard G Madden, Catherine Jones, Miriam Fritz, Claudio Gobbi, Giorgia Melli, Emanuela Pasi, Jenny Herrod, Rebecca F Lissmann, Hamad H Ashraf, Mohamed Abdelrahim, Omar A B A L Masri, Montserrat Fraga, David Benninger, Thierry Kuntzer, Vincent Aubert, Roland Sahli, Darius Moradpour, Hélène Blasco-Perrin, Shahram Attarian, Rene Gérolami, Philippe Colson, Maria T Giordani, Johannes Hartl, Sven Pischke, Nan X Lin, Brendan N Mclean, Richard P Bendall, Marcus Panning, Jean-Marie Peron, Nassim Kamar, Jacques Izopet, Bart C Jacobs, Nens van Alfen, Baziel G M van Engelen
OBJECTIVE: To determine the clinical phenotype and outcome in hepatitis E virus-associated neuralgic amyotrophy (HEV-NA). METHODS: Cases of NA were identified in 11 centers from 7 European countries, with retrospective analysis of demographics, clinical/laboratory findings, and treatment and outcome. Cases of HEV-NA were compared with NA cases without evidence of HEV infection. RESULTS: Fifty-seven cases of HEV-NA and 61 NA cases without HEV were studied...
August 2, 2017: Neurology
https://www.readbyqxmd.com/read/28767462/efficacy-and-safety-of-simeprevir-or-daclatasvir-in-combination-with-sofosbuvir-for-the-treatment-of-hepatitis-c-genotype-4-infection
#17
Mohammed A Babatin, Abdullah S Alghamdi, Ali Albenmousa, Abdulla Alaseeri, Mahdi Aljarodi, Haziz Albiladi, Ashwaq Alsahafi, Mohammed Almugharbal, Hammad S Alothmani, Faisal M Sanai, Khalid I Bzeizi
INTRODUCTION: The combination of sofosbuvir (SOF) with simeprevir (SMV) or daclatasvir (DCV) is very effective in treating hepatitis C virus (HCV) infection, particularly genotype (GT) 1. However, the data on GT4 are very limited. We aimed to determine the efficacy and safety of SOF in combination with either SMV or DCV in GT4-infected patients. PATIENTS AND METHODS: In this real life, prospective, observational study, HCV (GT4) patients (n=96) were evaluated in 2 groups on the basis of the 12-week treatment regimen they received...
August 1, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28756625/sofosbuvir-velpatasvir-in-patients-with-hepatitis-c-virus-genotypes-1-6-and-compensated-cirrhosis-or-advanced-fibrosis
#18
Tarik Asselah, Stefan Bourgeois, Stephen Pianko, Stefan Zeuzem, Mark Sulkowski, Graham R Foster, Lingling Han, John McNally, Anu Osinusi, Diana M Brainard, G Mani Subramanian, Edward J Gane, Jordan J Feld, Alessandra Mangia
BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection and advanced fibrosis (Metavir F3) or cirrhosis (Metavir F4) have been identified as a priority group for immediate treatment. We evaluated the safety and efficacy of sofosbuvir-velpatasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis or advanced fibrosis. METHODS: This retrospective analysis included 501 patients with compensated cirrhosis or advanced fibrosis (F3/F4), as defined by >0...
July 30, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28755163/cxcl9-11-polymorphisms-are-associated-with-liver-fibrosis-in-patients-with-chronic-hepatitis-c-a-cross-sectional-study
#19
María Ángeles Jiménez-Sousa, Ana Zaida Gómez-Moreno, Daniel Pineda-Tenor, Luz Maria Medrano, Juan José Sánchez-Ruano, Amanda Fernández-Rodríguez, Tomas Artaza-Varasa, José Saura-Montalban, Sonia Vázquez-Morón, Pablo Ryan, Salvador Resino
BACKGROUND AND AIMS: CXCL9-11 polymorphisms are related to various infectious diseases, including hepatitis C virus (HCV) infection. In this study, we analyzed the association between CXCL9-11 polymorphisms and liver fibrosis in HCV-infected patients. METHODS: We performed a cross-sectional study in 389 patients who were genotyped for CXCL9-11 polymorphisms (CXCL9 rs10336, CXCL10 rs3921, and CXCL11 rs4619915) using the Sequenom's MassARRAY platform. The primary outcome variable was the liver stiffness measurement (LSM)...
December 2017: Clinical and Translational Medicine
https://www.readbyqxmd.com/read/28753243/a-sero-epidemiological-survey-of-the-effect-of-hepatitis-b-vaccine-and-hepatitis-b-and-c-virus-infections-among-elementary-school-students-in-siem-reap-province-cambodia
#20
Mayumi Fujimoto, Channarena Chuon, Shintaro Nagashima, Chikako Yamamoto, Ko Ko, Sonama Svay, Sirany Hok, Olline Lim, Masayuki Ohisa, Tomoyuki Akita, Keiko Katayama, Junko Matsuo, Kazuaki Takahashi, Junko Tanaka
AIM: This study aimed to survey the prevalence and incidence of hepatitis B (HBV) and hepatitis C virus (HCV) infection among elementary school students in Siem Reap province, Cambodia and to evaluate the effects of a national infant HBV vaccination program introduced in 2001. METHODS: The 3(rd) grade students during 2011, 2012 and 2013 Academic years were enrolled in this study and they became 5(th) or 6(th) grade students in 2014-2015 Academic year at their second time examination...
July 28, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
keyword
keyword
85439
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"